Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Aaron Michels
University of Colorado Denver, Department: Pediatrics
Should you be removed from our database? Contact us at [email protected]. Read more below.
ImmunoMolecular Therapeutics, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Michels has a significant financial interest due to his equity/ownership interest in the company ImmunoMolecular Therapeutics, LLC. This company holds a patent for the therapeutic use of D-alpha-methyldopa for the prevention or treatment of autoimmune diseases, such as autoimmune diabetes. The company also has patents/pending patents for extended release versions of L-alpha-methyldopa and D-alpha-methyldopa.
TN-23 METHYLDOPA FOR REDUCTION OF DQ8 ANTIGEN PRESENTATION IN AT-RISK SUBJECTS FOR TYPE 1 DIABETES MELLITUS is a clinical trial that TrialNet is preparing to launch. This study uses L-alpha-methyldopa for the prevention of type 1 diabetes. The study drug L-alpha-methyldopa is generic Aldomet and has been clinically used for over 50 years.
ImmunoMolecular Therapeutics, LLC has no patents on the use of generic L-alpha-methyldopa (Aldomet) for use in autoimmune diabetes. Because a positive result in this study could benefit ImmunoMolecular Therapeutics, LLC and their drug development, the University of Colorado Denver | Anschutz Medical Campus (UC Denver) Conflict of Interest and Commitment Committee (Committee) finds that Dr. Michels’ participation in this study poses a financial conflict of interest.
TrialNet: Diabetes Type 1 Prevention
There are more than 1 .5 million with Type 1 diabetes in the United States and probably as many who may develop it over their lifetime. The cost of treating this disease and its complications is a major issue for our health care system. Type 1 Diabetes TrialNet was constituted to find therapies which would prevent and reverse this autoimmune disease. Although progress has been made to temporarily halt disease progression, more work to permanently stop it remains. It is the ongoing goal of the TrialNet Network through the excellent conduct of clinical trials and incorporation of relevant mechanistic studies to find treatments that can achieve these ends.
Filed on August 22, 2018.
Tell us what you know about Aaron Michels's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.